Navigation Links
MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
Date:10/15/2009

GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

"Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases," said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma."

The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows:

  • Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis (Oral Presentation)-Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B
  • In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis - Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 8
  • Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001 -Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587
  • MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases - Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 401
  • Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma - Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1062
  • Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment - Brian Naiman, MS., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 666
  • Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis -Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1053
  • Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma - Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1065
  • Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis - Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1067
  • Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration - Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1331
  • CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-a, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study (Oral Presentation) - Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1926

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
2. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. MedImmune Announces Zook as President
5. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
8. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
10. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
11. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):